Suspension of trading

Spexis AG Stock Swiss Exchange

Stocks

POLN

CH0106213793

Pharmaceuticals

OTC Markets Traded
Delayed 03:36:37 20/03/25 am AEDT 5-day change 1st Jan Change
0.0100 CHF -75.00% Intraday chart for Spexis AG -75.00% -84.62%
3 months-82.46%
6 months-77.58%
1 week-75.00%
3 months-82.46%
6 months-77.58%
Current year-84.62%
1 week 0.01
Extreme 0.01
0.04
1 month 0.01
Extreme 0.01
0.06
3 years 0.01
Extreme 0.01
1.35
5 years 0.01
Extreme 0.01
9.45
Manager TitleAgeSince
Chief Executive Officer 64 31/03/2022
Director of Finance/CFO - 01/08/2024
Director TitleAgeSince
Chairman 70 20/11/2019
Director/Board Member 65 01/06/2013
Director/Board Member 80 30/12/2021
Change 5-day change 1-year change 3-year change Capi.($)
-75.00%-75.00%-88.89%-99.22% 817K
+0.31%-3.08%+37.16%-5.65% 78.04B
-1.79%-0.05%+487.35%+24.33% 57.48B
+2.68%-0.93%-16.09%-35.72% 57.4B
-0.56%-2.21%-11.34%+27.29% 48.81B
+1.99%-0.24%+2.09%+154.49% 45.5B
-0.45%+2.89%+52.55%-14.70% 32.08B
+0.31%-2.07%+46.53%+91.91% 24.62B
+3.53%-4.39%+1.31%+156.56% 20.77B
+2.28%0.00%+64.84%+100.89% 15.75B
Average +0.90%-3.87%+57.55%+40.02% 42.27B
Weighted average by Cap. +0.61%-3.71%+87.82%+36.53%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!